Ipamorelin + CJC-1295
IAM no longer offers ipamorelin with CJC-1295. This page remains available to explain the combination, its historical preparations and the research behind it. CJC-1295 is a GHRH analog and ipamorelin is a GHRP. There is no medication supply or intake offer for this combination.
About this treatment
Understand two approaches to growth hormone signaling.
Ipamorelin and CJC-1295 act on different signals involved in growth hormone release. IAM no longer offers this combination. This overview remains available to explain the research and the differences between historical compounded preparations and the ingredients studied.
Two signals, one hormone pathway
CJC-1295 is related to growth hormone-releasing hormone, which signals the pituitary gland. Ipamorelin acts through the ghrelin receptor, another route involved in growth hormone release. Human studies have measured changes in growth hormone and IGF-1 after these compounds. These measurements explain the interest in combining their different mechanisms.
The exact preparation matters
Historical injectable and troche preparations paired ipamorelin with a CJC component. A rapid-dissolve tablet also contained sermorelin, another growth hormone-releasing hormone analog. The injectable's ingredient name specified tetra-substituted GRF 1-29 acetate. The long-acting CJC research used a drug affinity complex, or DAC, and should not be assumed to describe these historical preparations.
Look beyond a hormone number
A change in growth hormone or IGF-1 does not by itself establish a change in sleep, activity or recovery. If you are reviewing an existing prescription, bring its ingredient list and your laboratory results to your prescribing provider. Ask how the results relate to your symptoms and how unexpected swelling, headaches or a racing heartbeat should be handled.
Research and product information
Human studies tested the ingredients separately, including long-acting injected CJC-1295 and intravenous ipamorelin. They do not establish recovery or body-composition benefits for the historical compounded combination described here. FDA identifies limited safety information and potential immune reactions, with heart-rate and flushing reactions reported for CJC-1295.
- Teichman et al. Long-acting CJC-1295 and growth hormone secretion in healthy adults (2006)
- Gobburu et al. Ipamorelin pharmacokinetics and growth hormone responses in human volunteers (1999)
- FDA: safety information for certain bulk substances used in compounding
- FDA: understanding compounded drug preparations
Sources checked .
Explore research and care options
Read the overview
Understand the two ingredients and what the human studies measured.
Check the preparation
Distinguish historical compounded forms from the preparations used in research.
Explore current treatments
Browse treatments currently offered by IAM or discuss existing care with your prescribing provider.
About this treatment
What it is
A combination of two peptides involved in growth hormone signaling: a GHRH analog and a GHRP. Historical compounded preparations included an injectable and a troche. These preparations are not FDA-approved, and IAM no longer offers the combination.
Who it's for
People who want to understand this combination or revisit information about a previous prescription. If you have questions about existing treatment, contact your prescribing provider.
Historical preparations
Previously listed: injectable PF 15mg/
